COCRYSTAL PHARMA ($COCP) is expected to release its quarterly earnings data on Monday, April 7th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.54 per share.
You can see Quiver Quantitative's $COCP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COCRYSTAL PHARMA Hedge Fund Activity
We have seen 8 institutional investors add shares of COCRYSTAL PHARMA stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 25,673 shares (-67.9%) from their portfolio in Q4 2024, for an estimated $51,859
- VELAN CAPITAL INVESTMENT MANAGEMENT LP added 10,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,200
- UBS GROUP AG added 5,220 shares (+573.6%) to their portfolio in Q4 2024, for an estimated $10,544
- MORGAN STANLEY added 5,046 shares (+8.5%) to their portfolio in Q4 2024, for an estimated $10,192
- RENAISSANCE TECHNOLOGIES LLC removed 4,200 shares (-3.2%) from their portfolio in Q4 2024, for an estimated $8,484
- GEODE CAPITAL MANAGEMENT, LLC added 2,630 shares (+4.0%) to their portfolio in Q4 2024, for an estimated $5,312
- TOWER RESEARCH CAPITAL LLC (TRC) removed 1,913 shares (-69.7%) from their portfolio in Q4 2024, for an estimated $3,864
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
